Economic Evaluation 101 in Healthcare: Introduction to Economic Evaluation in Healthcare

NOTE: This article is the first in a series of 10 articles and is part of our Economic Evaluation in Healthcare 101 course. You can find a course overview and links to all 10 course modules here:

Introduction to Economic Evaluation in Healthcare

As healthcare systems across the globe face increasing demand and finite resources, economic evaluation has emerged as a vital tool for informing decisions about the allocation of health interventions. By comparing the costs and outcomes of different healthcare strategies, economic evaluation helps policymakers, clinicians, and payers prioritize investments that deliver the greatest value for money. This essay provides a foundational overview of economic evaluation in healthcare, structured around four key dimensions: its definition, its importance in decision-making, the underpinning economic principles, and the types of economic evaluations most commonly used in the field.

What is Economic Evaluation?

Economic evaluation is a comparative analysis of alternative courses of action in terms of both their costs and consequences (Drummond et al., 2015). In the context of healthcare, this often involves evaluating new treatments, technologies, or public health programs to determine whether they offer good value relative to existing alternatives. Unlike simple cost analysis, economic evaluation goes further by explicitly linking financial inputs to health outcomes.

A defining feature of economic evaluation is the systematic approach it takes: identifying, measuring, valuing, and comparing both costs (e.g., direct medical costs, indirect costs) and consequences (e.g., life years gained, quality-adjusted life years or QALYs). The ultimate goal is to inform resource allocation decisions that maximize health benefits under budget constraints.

Importance of Economic Evaluation in Healthcare Decision-Making

Healthcare systems worldwide operate under conditions of budgetary limitations, yet face rising demand due to aging populations, chronic disease burdens, and rapid technological innovation. Economic evaluation offers a structured, evidence-based method to make choices about which interventions to fund, scale, or disinvest.

For example, health technology assessment (HTA) agencies such as the National Institute for Health and Care Excellence (NICE) in the UK and the Canadian Agency for Drugs and Technologies in Health (CADTH) routinely use economic evaluations as part of their reimbursement and guideline development processes (O’Mahony, 2015). These assessments help determine whether a new cancer drug, for instance, offers sufficient clinical benefit relative to its cost to warrant public funding.

Moreover, economic evaluation supports transparency and accountability in decision-making. It enables stakeholders to justify choices about which treatments to cover and provides a defensible framework for declining to fund those that are not cost-effective. As such, it enhances both the efficiency and the equity of healthcare delivery by promoting fair and informed resource allocation.

Key Principles: Scarcity, Opportunity Cost, and Efficiency

Economic evaluation is grounded in three core economic concepts: scarcity, opportunity cost, and efficiency.

Scarcity reflects the fundamental reality that resources—whether financial, human, or technological—are limited. In healthcare, this means not every possible service or innovation can be provided to every individual at all times.
Opportunity cost refers to the benefits foregone by choosing one option over another. In economic evaluations, this principle is essential: the cost of funding a new health intervention is not just its price tag, but also the loss of the health benefits that could have been achieved had those resources been spent elsewhere.
Efficiency in healthcare is about achieving the maximum possible health gain from the available resources. Economic evaluation aids in identifying efficient choices—interventions that deliver the greatest health outcomes per dollar spent—thereby improving overall system performance.

These principles are not just theoretical; they have practical implications for how interventions are prioritized. For example, investing in preventive care for chronic diseases may offer greater long-term value compared to high-cost treatments with limited benefits.

Types of Economic Evaluations in Healthcare

Several methodological approaches fall under the umbrella of economic evaluation, each with its unique characteristics and suitable applications. The main types include:

Cost-Minimization Analysis (CMA): This method is used when two or more interventions are already proven to have equivalent outcomes. The focus is solely on identifying the least costly option. However, its use is limited because such equivalency is rarely established in practice.
Cost-Effectiveness Analysis (CEA): CEA compares interventions based on the cost per unit of natural health outcome, such as life-years gained, cases prevented, or blood pressure reduction. It is particularly useful when comparing interventions with the same health outcome but different levels of effectiveness and cost.
Cost-Utility Analysis (CUA): A subtype of CEA, CUA incorporates both the quantity and quality of life, usually expressed as QALYs. This allows for broader comparisons across disease areas and interventions, making it the preferred method in many HTA settings. For example, NICE frequently uses cost per QALY thresholds to determine the affordability of new treatments (NICE, 2022).
Cost-Benefit Analysis (CBA): CBA translates both costs and benefits into monetary terms, allowing direct comparison between them. Though appealing in theory, its application in healthcare is limited due to the difficulty and ethical concerns of assigning monetary value to health outcomes or human life.
Cost-Consequence Analysis (CCA): This approach lists multiple outcomes and costs without aggregating them into a single metric. It allows decision-makers to weigh the trade-offs themselves, though it lacks the summary power of QALY-based metrics.
Budget Impact Analysis (BIA): BIA evaluates the financial consequences of adopting a new healthcare intervention within a specific budget context, such a sa health plan, hospital system, or national payer. Unlike other methods described above, which focus on value for money (e.g., cost per QALY gained), BIA examines affordability—estimating how the introduction of a new treatment will change total healthcare spending over a short- to medium-term time horizon (typically 1–5 years)

Each method serves different policy and clinical contexts, and the choice of evaluation depends on the nature of the intervention, the available data, and the decision-making environment.

Conclusion

Economic evaluation has become an indispensable component of modern healthcare decision-making. By systematically comparing costs and outcomes, it offers a robust framework to ensure that limited resources are used to generate the greatest possible health gains. Grounded in the principles of scarcity, opportunity cost, and efficiency, and operationalized through several methodological approaches, economic evaluation enhances the transparency, accountability, and fairness of health resource allocation. As health systems face mounting pressures and complex choices, the role of economic evaluation will only grow in importance.

References

Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the Economic Evaluation of Health Care Programmes (4th ed.). Oxford University Press.
O’Mahony, J. F. (2015). QALYs and their role in the NICE decision-making process. Prescriber, 26(9), 29–33. https://doi.org/10.1002/psb.1396
National Institute for Health and Care Excellence (NICE). (2022). Guide to the Methods of Technology Appraisal 2013. https://www.nice.org.uk/process/pmg9/